Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/02/063322
CTRI/2024/02/063322
Not Yet Recruiting
Phase 4

A Clinical Study to evaluate the Safety and Efficacy of ACELABS Lumiere Rebalancing Diamond Drop for advanced skin brightening. - NI

Bright Diva Pte. Ltd.0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Bright Diva Pte. Ltd.
Status
Not Yet Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Pms

Investigators

Sponsor
Bright Diva Pte. Ltd.

Eligibility Criteria

Inclusion Criteria

  • •1\.Gender: Male or Female aged between 20 to 30, with minimum F:M distribution ratio of 2:1
  • •2\.Subject willing to give written informed consent
  • •3\.Women of child bearing potential must have a negative urine pregnancy test
  • •4\.Free of any systemic and dermatologic disorder, which in the opinion of the investigator, will interface with the study results or increase the risk of AE.
  • •5\.Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion Criteria

  • •1\.Subjects who are pregnant, breast feeding, or planning to become pregnant during the study
  • •2\.Have any evidence of systematic cancer, squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition.
  • •3\.Have open sore or open lesions in the treatment area
  • •4\.Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product.
  • •5\.Have participated in any interventional clinical trial in the previous 30 days.
  • •6\.Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents.
  • •7\.Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), blood purifiers and including corticosteroids.
  • •8\.Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting
Phase 2
Effect of Decoction of Cuscuta Reflexa and local application of Saussurea Lappa and Honey in the management of Melasma.
CTRI/2021/03/032083Central Council of Research in Unani Medicine New Delhi
Not Yet Recruiting
Phase 4
To study the effect of Panchakarma Essential in male patients with anxiety.
CTRI/2023/07/055723Mprex Healthcare Pvt. Ltd.
Not Yet Recruiting
Phase 4
To study the effect of Panchakarma Essential in female patients with anxiety.
CTRI/2023/08/056234Mprex Healthcare Pvt. Ltd.
Not Yet Recruiting
N/A
To study the effect of Panchakarma Essential in reducing symptoms with cardiopulmonarydisordersHealth Condition 1: I249- Acute ischemic heart disease, unspecified
CTRI/2023/11/060197Mprex Healthcare Pvt.Ltd. Wakad, pune
Not Yet Recruiting
Phase 4
To study the effect of Panchakarma Essential (Nirgundi-based formulation) in Knee Osteoarthritis.
CTRI/2023/07/055689Mprex Healthcare Pvt. Ltd.